DNA

Ikena Oncology Provides Research & Development Update on IK-930 Program Targeting the Hippo Pathway

Clinical collaboration with AstraZeneca announced for the evaluation of osimertinib in combination with IK-930 for patients with EGFR-mutant lung cancers…

2 years ago

NeuBase Therapeutics Announces Strategic Restructuring Focused on Advancing Its Platform in Gene Editing

Workforce reductions of ~60% and implementation of a robust cost reduction plan are expected to extend the Company’s cash runway…

2 years ago

Aligos Therapeutics Initiates Dosing In Healthy Volunteers With siRNA Drug Candidate ALG-125755

Single ascending doses to be evaluated in healthy volunteers in Q4 2022 Single ascending doses to be evaluated in subjects…

2 years ago

Emory Healthcare Researcher Wins Two Awards Using Konica Minolta’s AI Analysis Tool With Dynamic Digital Radiography in Shoulder Pathology

KMHA Dynamic Digital Radiography - Shoulder Dynamic Digital Radiography enables the visualization of anatomy in motion, so clinicians can visualize…

2 years ago

Bavarian Nordic Enters Agreement with Switzerland on the Supply of Smallpox and Monkeypox Vaccine

Switzerland has ordered 100,000 doses of smallpox and monkeypox vaccine with deliveries starting imminentlyBavarian Nordic will seek regulatory approval of…

2 years ago

Enzo Biochem Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Update

- Enzo Life Sciences reports revenue of $32.6 million and 8% growth in FY 2022, net of FX - Company…

2 years ago

LIXTE BIOTECHNOLOGY ANNOUNCES APPROVAL OF A PHASE 1B/2 RANDOMIZED TRIAL OF DOXORUBICIN +/-LB-100 IN ADVANCED SOFT TISSUE SARCOMAS TO BE CONDUCTED BY THE SPANISH SARCOMA GROUP

PASADENA, CA, Oct. 13, 2022 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), (“LIXTE” or the “Company”), a clinical-stage…

2 years ago

Codex DNA Announces Plan to Change Corporate Name to Telesis Bio

Novel name reflects expansion of capabilities and solutionsSAN DIEGO, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY),…

2 years ago

Entasis Therapeutics, a Wholly Owned Subsidiary of Innoviva, Announces Data on SUL-DUR to be Presented at IDWeek 2022

Six abstracts selected for presentation, including three oral presentationsWALTHAM, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc.,…

2 years ago

Codiak Presents Preclinical Data Demonstrating its Pan Beta-Coronavirus Vaccine Elicits Broad Protective Immunity Against Known Variants of SARS-CoV-2 and Related Sarbecoviruses

– Data support advancement of Codiak’s engineered exosome bivalent vaccine candidate toward IND-enabling studies – CAMBRIDGE, Mass., Oct. 12, 2022…

2 years ago